Abstract
Antiplatelet therapy is of paramount importance in the treatment and prevention of adverse cardiovascular events and stroke. Drug-drug interactions (DDIs) among antiplatelet therapies have been growing in both prevalence and clinical importance. Most DDIs with antiplatelet therapies are pharmacodynamic in nature. DDIs with thienopyridines and proton pump inhibitors have resulted in advisories from regulatory agencies although the full significance of this interaction is unknown. Other DDIs with thienopyridines may potentially exist with statins, calcium channel blockers, and warfarin but lack demonstratable evidence of harm. Aspirin may interact with a variety of medications, including non-steroidal anti-inflammatory agents and angiotensin inhibitors. DDIs requiring some level of intervention may also be present with dipyridamole and cilostazol. Overall, DDIs with antiplatelet drugs are biologically plausible and potentially clinically relevant. However, the full significance of these DDIs is largely unknown due to reliance on research of voluntary reports, registries, and claims databases to determine significance.
Keywords: Antiplatelets, drug interactions, aspirin, thienopyridines, dipyridamole, cilostazol, cardiovascular disease, NSAIDs, calcium channel blockers, pharmacodynamic, pharmacokinetic
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Drug-Drug Interactions Associated with Antiplatelet Therapy
Volume: 9 Issue: 4
Author(s): Steven P. Dunn and Tracy E. Macaulay
Affiliation:
Keywords: Antiplatelets, drug interactions, aspirin, thienopyridines, dipyridamole, cilostazol, cardiovascular disease, NSAIDs, calcium channel blockers, pharmacodynamic, pharmacokinetic
Abstract: Antiplatelet therapy is of paramount importance in the treatment and prevention of adverse cardiovascular events and stroke. Drug-drug interactions (DDIs) among antiplatelet therapies have been growing in both prevalence and clinical importance. Most DDIs with antiplatelet therapies are pharmacodynamic in nature. DDIs with thienopyridines and proton pump inhibitors have resulted in advisories from regulatory agencies although the full significance of this interaction is unknown. Other DDIs with thienopyridines may potentially exist with statins, calcium channel blockers, and warfarin but lack demonstratable evidence of harm. Aspirin may interact with a variety of medications, including non-steroidal anti-inflammatory agents and angiotensin inhibitors. DDIs requiring some level of intervention may also be present with dipyridamole and cilostazol. Overall, DDIs with antiplatelet drugs are biologically plausible and potentially clinically relevant. However, the full significance of these DDIs is largely unknown due to reliance on research of voluntary reports, registries, and claims databases to determine significance.
Export Options
About this article
Cite this article as:
P. Dunn Steven and E. Macaulay Tracy, Drug-Drug Interactions Associated with Antiplatelet Therapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (4) . https://dx.doi.org/10.2174/187152511798120912
DOI https://dx.doi.org/10.2174/187152511798120912 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
Current Enzyme Inhibition Adverse Drug Reactions in Hospitals: A Narrative Review
Current Drug Safety The Road to Device Miniaturization in Echocardiography
Recent Patents on Medical Imaging Antioxidant and Antiinflammatory Activities of Curcumin on Diabetes Mellitus and its Complications
Current Pharmaceutical Design Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review
Current Vascular Pharmacology Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Social Determinants, Race, and Brain Health Outcomes: Findings from the Chicago Health and Aging Project
Current Alzheimer Research Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry High-Throughput Proteomics: A New Tool for Quality and Safety in Fishery Products
Current Protein & Peptide Science Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Current Pharmaceutical Design Nutrition Status and Weight Management in Chinese Women
Current Women`s Health Reviews Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design Role of Adiponectin in Obesity, Hypertension, and Metabolic Syndrome
Current Hypertension Reviews Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Biological Therapies For Inflammatory Bowel Disease: Research DrivesClinics
Mini-Reviews in Medicinal Chemistry Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Cardiovascular Aspect of Beta-Thalassaemia
Cardiovascular & Hematological Agents in Medicinal Chemistry